Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally?

Core Insights - Illumina's shares have increased by 44.8% over the past year, significantly outperforming the industry and S&P 500 [1][9] - The company is focused on long-term growth through its core sequencing business, multiomics expansion, and enhanced services, data, and software capabilities [2][4] Company Performance - Illumina's core sequencing business is experiencing growth, particularly with the NovaSeq X platform, which has driven a 7% increase in ex-China revenues in Q4 [4][9] - The company achieved its second-highest quarterly placements of NovaSeq X since its launch in 2023 [5] Strategic Initiatives - Illumina is expanding into multiomics through acquisitions, such as SomaLogic, and has launched the Illumina Connected Multiomics platform [6] - The introduction of the BioInsight business and the Billion Cell Atlas data product has garnered strong interest from biopharma partners [7] Financial Health - Non-GAAP gross margins improved by 165 basis points, and non-GAAP operating margins expanded by 400 basis points year-over-year [10] - As of the end of Q4, Illumina had cash and short-term investments totaling $1.63 billion, with $500 million in short-term debt, indicating a strong liquidity position [10] Market Challenges - In March 2025, China imposed a ban on imports of Illumina's NGS sequencers, which poses a significant challenge in a market with high sequencing demand [11] - The company is also facing macroeconomic pressures, including inflation and currency fluctuations [11] Future Projections - The Zacks Consensus Estimate predicts a 6.2% increase in EPS for 2026 and a 14.8% increase for 2027, with revenues expected to grow to $4.54 billion in 2026 and $4.83 billion in 2027 [12]